UPDATE: Rexahn Pharmaceuticals (RNN) Posts Q1 Loss of 9c/Share; Updates on Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to UPDATE: Rexahn Pharmaceuticals (RNN) Posts Q1 Loss of 9c/Share; Updates on Pipeline

Roth Affirms Rexahn (RNN) at 'Buy'; Things Shaping Up for Solid Second-Half 2014

May 15, 2014 8:14 AM EDT

Roth Capital maintains Rexahn Pharmaceuticals (AMEX: RNN) at Buy with a target price of $3. Ahead of the bell, Rexahn reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02).

Analyst Joseph Pantginis commented, The financial results currently do not impact our investment case. Rexahn has three clinical-stage assets. Archexin is a potentially best-in-class Akt1 inhibitor. A Phase IIa study of the drug in pancreatic cancer showed that the drug is safe and well tolerated and demonstrated... More